Results 151 to 160 of about 119,784 (210)

Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center. [PDF]

Front Immunol
Srinivasan C, Ritchie B, Adatia A.
europepmc   +1 more source

Association of Endothelial Cell Activation with Acute Kidney Injury during Coronary Angiography and the Influence of Recombinant Human C1 Inhibitor-A Secondary Analysis of a Randomized, Placebo-Controlled, Double-Blind Trial. [PDF]

Biomedicines
Moser S, Araschmid L, Panagiotou A, Bonati LH, Breidthardt T, Fahrni G, Kaiser C, Jeger R, Trendelenburg M, Osthoff M.   +9 more
europepmc   +1 more source

Acute Abdominal Pain as the Initial Presentation of an Acquired C1 Inhibitor Deficiency. [PDF]

GE Port J Gastroenterol
Pinto AR, Carolino F.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Acquired C1 Inhibitor Deficiency

Immunology and Allergy Clinics of North America, 2017
Acquired angioedema due to C1-INH deficiency (C1-INH-AAE) can occur when there are acquired (not inherited) deficiencies of C1-INH. A quantitative or functional C1-INH deficiency with negative family history and low C1q is diagnostic of C1-INH-AAE. The most common conditions associated with C1-INH-AAE are autoimmunity and B-cell lymphoproliferative ...
Iris M, Otani, Aleena, Banerji
openaire   +2 more sources

Deficiencies of C1 inhibitor

Best Practice & Research Clinical Gastroenterology, 2005
Hereditary and acquired deficiencies of the C1 inhibitor result in a single prominent symptom, namely angioedema. Angioedema may involve the skin, the gastrointestinal tract or the upper airway. Genetically determined defects in C1INH cause hereditary angioedema.
Fred S, Rosen, Alvin E, Davis
openaire   +2 more sources

C1 inhibitor deficiency: management

Clinical and Experimental Dermatology, 2005
This is the second of two articles on C1 inhibitor deficiency based on a recent UK consensus document covering its diagnosis and management in adults and children. This summary focuses on the management of the disorder including prophylaxis, emergency treatment and special situations such as pregnancy and dental care.
M M, Gompels, R J, Lock
openaire   +2 more sources

Monocyte C1‐inhibitor synthesis in patients with C1‐inhibitor deficiency

European Journal of Clinical Investigation, 1989
Abstract. Monocytes of seven out of eight patients with type 1 C1‐inhibitor (C1‐inh) deficiency (HAE) produced 40% as much C1‐inh as monocytes from normal donors (controls). In contrast, monocytes from three patients with type 2 and three patients with acquired C1‐inh deficiency produced similar amounts of Cl‐inh as controls. Recombinant γ‐interferon (
D F, Lappin, A R, McPhaden, P L, Yap, P E, Carter, G D, Birnie, J E, Fothergill, K, Whaley   +6 more
openaire   +2 more sources

C1-inhibitor deficiency and angioedema

Molecular Immunology, 2001
C1-inhibitor deficiency can be inherited or acquired; both conditions lead to recurrent angioedema that can be life threatening when the larynx is involved (hereditary angioedema, HAE; acquired angioedema, AAE). The genetic defect is due to the heterozygous deficiency of C1-Inh that is transmitted as an autosomal dominant trait.
A. Carugati, E. Pappalardo, L.C. Zingale, M. Cicardi   +3 more
openaire   +3 more sources

C1-inhibitor autoantibodies in SLE

Lupus, 2010
The presence of anti-C1-inhibitor (anti-C1-INH) autoantibodies is a hallmark of acquired C1-inhibitor deficiency. However, only scarce data are available on their prevalence, diagnostic value, and/or significance in systemic lupus erythematosus (SLE).
T, Mészáros, G, Füst, H, Farkas, L, Jakab, G, Temesszentandrási, G, Nagy, E, Kiss, P, Gergely, M, Zeher, Z, Griger, L, Czirják, R, Hóbor, A, Haris, K, Polner, L, Varga   +14 more
openaire   +2 more sources

C1 inhibitor: molecular and clinical aspects

Springer Seminars in Immunopathology, 2005
C1 inhibitor (C1-INH) is a serine protease inhibitor (serpins) that inactivates several different proteases in the complement, contact, coagulation, and fibrinolytic systems. By its C-terminal part (serpin domain), characterized by three beta-sheets and an exposed mobile reactive loop, C1-INH binds, and blocks the activity of its target proteases.
M. Cicardi, L. Zingale, A. Zanichelli, E. Pappalardo, CICARDI, BENEDETTA   +4 more
openaire   +2 more sources